Infectious complications of acute and chronic GVHD

Best Practice and Research: Clinical Haematology

Volumn 21, Issue 2, 2008, Pages 343-356

  Young, Jo Anne H ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

aspergillosis; cytomegalovirus; hypogammaglobulinemia; opportunistic infection

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; BENZIMIDAVIR; CORTICOSTEROID; COTRIMOXAZOLE; DAPSONE; FLUCONAZOLE; GANCICLOVIR; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; MACROLIDE; OXYGEN; PEGINTERFERON; PENICILLIN G; PENTAMIDINE; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RITUXIMAB; UNINDEXED DRUG; VALACICLOVIR; VALGANCICLOVIR; VORICONAZOLE;

ACUTE GRAFT VERSUS HOST DISEASE; ASPERGILLOSIS; BACTERIAL INFECTION; BLOOD ANALYSIS; CANDIDA; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR LYMPHOCYTE INFUSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EPSTEIN BARR VIRUS; FUNGAL STRAIN; FUNGUS CULTURE; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; IMMUNOGLOBULIN DEFICIENCY; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; INFLUENZA VIRUS B; MONOTHERAPY; MYCOSIS; NAUSEA; NEISSERIA MENINGITIDIS; NONHUMAN; OPPORTUNISTIC INFECTION; PATIENT ASSESSMENT; PATIENT MONITORING; PENICILLIN RESISTANCE; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RESPIRATORY VIRUS; REVIEW; RISK ASSESSMENT; SEROLOGY; SIDE EFFECT; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS REACTIVATION; VIRUS STRAIN;

ANTI-INFECTIVE AGENTS; ANTIVIRAL AGENTS; BACTERIAL INFECTIONS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; OPPORTUNISTIC INFECTIONS; VACCINATION; VIRUS DISEASES; VIRUS LATENCY;

EID: 44049083634     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2008.02.017     Document Type: Review

References (47)

1. Walker C.M., van Burik J.A., De For T.E., et al. Cytomegalovirus infection after allogeneic transplantation: comparison of cord blood with peripheral blood and marrow graft sources. Biology of Blood and Marrow Transplantation 13 (2007) 1106-1115
2. Boeckh M., and Nichols W.G. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 103 (2004 Mar 15) 2003-2008
3. Osarogiagbon R.U., Defor T.E., Weisdorf M.A., et al. CMV antigenemia following bone marrow transplantation: risk factors and outcomes. Biology of Blood and Marrow Transplantation 6 (2000) 280-288
4. Boeckh M., Gooley T.A., Myerson D., et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88 (1996) 4063-4071
5. Winston D.J., Young I.A., Pullarkat V., et al. Maribavir prophylaxis against for prevention of cytomegalovirus infections in allogeneic stem-cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled dose-ranging study. Blood (2008) Feb 19 [epub ahead of print]
6. Meyers J.D., Reed E.C., Shepp D.H., et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. The New England Journal of Medicine 318 (1988) 70-75
7. Boeckh M., Kim H.W., Flowers M.E., et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood 107 (2006 Mar 1) 1800-1805
8. Emanuel D., Cunningham I., and Jules-Elysee K. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immunoglobulin. Annals of Internal Medicine 109 (1988) 777-782
9. Steer C.B., Szer J., Sasadeusz J., et al. Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir. Bone Marrow Transplantation 25 (2000) 657-664
10. Erard V., Guthrie K.A., Varley C., et al. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood 110 (2007 Oct 15) 3071-3077
11. Weinstock D.M., Boeckh M., and Sepkowitz K.A. Postexposure prophylaxis against varicella zoster virus infection among hematopoietic stem cell transplant recipients. Biology of Blood and Marrow Transplantation 12 (2006 Oct) 1096-1097
12. VariZIG for prophylaxis after exposure to varicella. Medical Letter on Drugs and Therapeutics 48 (2006 Aug 14-28) 69-70
13. A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morbidity and Mortality Weekly Report 55 (2006 Mar 3) 209-210
14. Brunstein C.G., Weisdorf D.J., Defor T., et al. Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood 108 (2006 Oct 15) 2874-2880
15. Bogunia-Kubik K., Mlynarczewska A., Jaskula E., et al. The presence of IFNG 3/3 genotype in the recipient associates with increased risk for Epstein-Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology 132 (2006 Feb) 326-332
16. Aalto S.M., Juvonen E., Tarkkanen J., et al. Lymphoproliferative disease after allogeneic stem cell transplantation - pre-emptive diagnosis by quantification of Epstein-Barr virus DNA in serum. Journal of Clinical Virology 28 (2003 Dec) 275-283
17. Cohen J.M., Cooper N., Chakrabarti S., et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning. Leukemia & Lymphoma 48 (2007 Feb) 256-269
18. Lau G.K., He M.L., Fong D.Y., et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36 (2002) 702-709
19. Knoll A., Boehm S., Hahn J., et al. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. Journal of Viral Hepatitis 14 (2007 Jul) 478-483
20. Fouillard L., Serfaty L., and Gozlan J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation 37 (2006 Mar) 625-626
21. Robin M., Porcher R., De Castro Araujo R., et al. Risk factors for late infections after allogeneic hematopoietic stem cell transplantation from a matched related donor. Biology of Blood and Marrow Transplantation 13 (2007 Nov) 1304-1312
22. Foster G.R. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus. Expert Opinion on Pharmacotheraphy 4 (2003) 685-691
23. Locasciulli A., Testa M., Pontisso P., et al. Hepatitis C virus genotypes and liver disease in patients undergoing allogeneic bone marrow transplantation. Bone Marrow Transplantation 19 (1997) 237-240
24. van Burik J.A., Ratanatharathorn V., Stepan D.E., et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases 39 (2004 Nov 15) 1407-1416
25. Stringer J.R., Beard C.B., Miller R.F., et al. A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerging Infectious Diseases 8 (2002) 891-896
26. Wald A., Leisenring W., van Burik J.A., et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. The Journal of Infectious Diseases 175 (1997) 1459-1466
27. Foy P.C., van Burik J.A., and Weisdorf D.J. Galactomannan antigen enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis after hematopoietic stem cell transplantation. Biology of Blood and Marrow Transplantation 13 (2007 Apr) 440-443
28. Cornely O.A., Maertens J., Winston D.J., et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. The New England Journal of Medicine 356 (2007 Jan 25) 348-359
29. Ullmann A.J., Lipton J.H., Vesole D.H., et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. The New England Journal of Medicine 356 (2007 Jan 25) 335-347
30. Wingard J., Carter S., Walsh T., et al. Results of a randomized, double-blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients. Blood 11 (2007) [abstract #163]
31. Herbrecht R., Denning D.W., Patterson T.F., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. The New England Journal of Medicine 347 (2002) 408-415
32. van Burik J.A., Hare R.S., Solomon H.F., et al. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clinical Infectious Diseases 42 (2006 Apr 1) e61-e65
33. Greenberg R.N., Mullane K., van Burik J.A., et al. Posaconazole as salvage therapy for zygomycosis. Antimicrobial Agents and Chemotherapy 50 (2006 Jan) 126-133
34. Gamis A.S., Gudnason T., Giebink G.S., et al. Disseminated infection with Fusarium in recipients of bone marrow transplants. Reviews of Infectious Diseases 13 (1991) 1077-1088
35. Boutati E.I., and Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 90 (1997) 999-1008
36. Prins C., Chavaz P., Tamm K., et al. Ecthyma gangrenosum-like lesions: a sign of disseminated Fusarium infection in the neutropenic patient. Clinical and Experimental Dermatology 20 (1995) 428-430
37. Hennequin C., Lavarde V., Poirot J.L., et al. Invasive Fusarium infections: a retrospective survey of 31 cases. The French 'Groupe d'Etudes des Mycoses Opportunistes' GEMO. Journal of Medical and Veterinary Mycology 35 (1997) 107-114
38. Sampathkumar P., and Paya C.V. Fusarium infection after solid-organ transplantation. Clinical Infectious Diseases 32 (2001) 1237-1240
39. Baden L.R., Katz J.T., Fishman J.A., et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76 (2003 Dec 15) 1632-1637
40. Haddad P.A., Repka T.L., and Weisdorf D.J. Penicillin-resistant Streptococcus pneumoniae septic shock and meningitis complicating chronic graft versus host disease: a case report and review of the literature. American Journal of Medicine 113 (2002) 152-155
41. Tauro S., Dobie D., Richardson G., et al. Recurrent penicillin-resistant pneumococcal sepsis after matched unrelated donor transplantation for refractory T cell lymphoma. Bone Marrow Transplantation 26 (2000) 1017-1019
42. Schutze G.E., Mason Jr. E.O., Wald E.R., et al. Pneumococcal infections in children after transplantation. Clinical Infectious Diseases 33 (2001) 16-21
43. Reed E.C., Bowden R.A., Dandliker P.S., et al. Efficacy of cytomegalovirus immunoglobulin in marrow transplant recipients with cytomegalovirus pneumonia. The Journal of Infectious Diseases 156 (1987) 641-645
44. Dykewicz C.A. Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Clinical Infectious Diseases 33 (2001) 139-144
45. Oliver M.R., Van Voorhis W.C., Boeckh M., et al. Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clinical Infectious Diseases 22 (1996) 521-524
46. Outbreaks of gastroenteritis associated with noroviruses on cruise ships - United States. MMWR Morbidity and Mortality Weekly Report 2002 51 (2002) 1112-1115
47. Minooee A., and Rickman L.S. Infectious diseases on cruise ships. Clinical Infectious Diseases 29 (1999) 737-743 quiz 744